Press Releases Fulgent Genetics, Inc.

Equities

FLGT

US3596641098

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
20.58 ^USD	+2.39%		+0.10%	-28.81%

Mar. 06	Piper Sandler Adjusts Price Target on Fulgent Genetics to $25 From $28, Maintains Neutral Rating	MT
Feb. 29	UBS Adjusts Fulgent Genetics Price Target to $25 From $35, Maintains Neutral Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024	Apr. 11	BU
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results	Feb. 28	BU
Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024	Feb. 13	BU
Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing	Feb. 09	PR
Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference	Nov. 14	BU
Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting	Nov. 03	BU
Fulgent Reports Third Quarter 2023 Financial Results	Nov. 03	BU
Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting	23-10-25	BU
Fulgent Genetics to Announce Third Quarter 2023 Financial Results on Friday November 3, 2023	23-10-17	BU
Fulgent Reports Second Quarter 2023 Financial Results	23-08-07	AQ
Fulgent Reports Second Quarter 2023 Financial Results	23-08-04	BU
Fulgent Genetics to Announce Second Quarter 2023 Financial Results on Friday, August 4, 2023	23-07-18	BU
Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers	23-06-05	BU
FULGENT GENETICS, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	23-05-18	AQ
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting	23-05-18	BU
FULGENT GENETICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	23-05-05	AQ
FULGENT GENETICS, INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	23-05-05	AQ
Fulgent Reports First Quarter 2023 Financial Results	23-05-05	BU
Fulgent Genetics to Announce First Quarter 2023 Financial Results on Friday May 5, 2023	23-04-20	BU
Mission Bio Partners with Fulgent Genetics to Broaden Accessibility of Single-Cell Multi-Omics for Drug Development and Clinical Research	23-04-11	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Fulgent Genetics, Inc.

Equities

FLGT

US3596641098

Press Releases

Filters